STTK: Shattuck Labs, Inc.
About
Shattuck Labs, Inc. engages in the research and development of dual-sided fusion proteins used for medical treatment of cancer and autoimmune disease. It primarily focuses on Agonist Redirected Checkpoint (ARC) and Gamma Delta T Cell Engagers (GADLEN) platforms. It develops a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and autoimmune diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.
Current Value
$1.161 Year Return
Current Value
$1.161 Year Return
Key Details
Market Cap
$54.42M
P/E Ratio
-0.75
1Y Stock Return
-50.22%
1Y Revenue Growth
382.75%
Dividend Yield
0.00%
Price to Book
0.6
Strategies that include STTK
Stock's related to STTK
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ACAD | 52.09% | $2.70B | -27.80% | 0.00% |
| PLAB | 49.97% | $1.52B | +12.34% | 0.00% |
| VRTX | 45.04% | $115.38B | +26.28% | 0.00% |
| CTLT | 35.41% | $10.69B | +47.79% | 0.00% |
| OPAD | 33.86% | $100.74M | -60.81% | 0.00% |
| DAWN | 32.67% | $1.36B | +13.42% | 0.00% |
| GPRO | 32.03% | $179.52M | -67.23% | 0.00% |
| RMAX | 31.04% | $215.33M | +23.09% | 0.00% |
| PLL | 30.45% | $238.11M | -56.47% | 0.00% |
| STHO | 30.20% | $150.51M | -5.99% | 0.00% |
| HAYN | 29.95% | $779.50M | +25.76% | 1.44% |
| CALM | 29.24% | $4.64B | +99.37% | 3.07% |
| CLDX | 29.23% | $1.66B | -10.82% | 0.00% |
| NTB | 28.73% | - | - | 4.69% |
| TPIC | 28.55% | $96.08M | -13.30% | 0.00% |
| OPRA | 28.46% | $1.75B | +63.06% | 4.03% |
| CION | 28.39% | - | - | 12.14% |
| PSTX | 27.42% | $269.98M | +6.13% | 0.00% |
| GHC | 26.57% | $3.98B | +49.71% | 0.76% |
| NWE | 26.54% | $3.41B | +10.00% | 4.68% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PRDO | -<0.01% | $1.73B | +56.77% | 1.74% |
| EAT | -0.04% | $5.43B | +244.22% | 0.00% |
| ZCMD | -0.05% | $2.80M | -88.67% | 0.00% |
| NDLS | -0.08% | $31.59M | -76.95% | 0.00% |
| PRPH | -0.14% | $18.14M | -82.61% | 0.00% |
| HIHO | 0.14% | $8.63M | 0.00% | 6.12% |
| CMG | 0.17% | $80.02B | +33.62% | 0.00% |
| CNC | 0.18% | $29.19B | -21.56% | 0.00% |
| SE | 0.19% | $60.12B | +197.12% | 0.00% |
| AWH | -0.21% | $11.44M | -76.87% | 0.00% |
| COCO | -0.23% | $2.01B | +24.49% | 0.00% |
| IMNN | -0.24% | $10.02M | -22.89% | 0.00% |
| NNVC | 0.25% | $19.66M | +25.69% | 0.00% |
| NLOP | 0.28% | $458.04M | +94.60% | 0.00% |
| GHG | 0.30% | $180.98M | -36.68% | 0.00% |
| IMRN | -0.31% | $10.31M | -5.04% | 0.00% |
| CAMT | 0.32% | $3.40B | +16.39% | 0.00% |
| CNK | 0.35% | $4.09B | +138.59% | 0.00% |
| FWONK | 0.36% | $20.20B | +25.99% | 0.00% |
| CYCN | 0.36% | $4.77M | -16.19% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AJG | -20.23% | $64.17B | +17.51% | 0.80% |
| LIN | -17.32% | $211.44B | +7.81% | 1.23% |
| ACGL | -16.29% | $36.00B | +16.84% | 0.00% |
| PGR | -16.16% | $149.10B | +57.29% | 0.45% |
| PFE | -15.54% | $142.24B | -17.16% | 6.73% |
| DAO | -14.06% | $159.28M | +25.62% | 0.00% |
| API | -13.79% | $299.01M | +33.12% | 0.00% |
| TW | -13.46% | $28.66B | +42.39% | 0.29% |
| RNR | -12.94% | $13.74B | +23.09% | 0.58% |
| LPLA | -12.70% | $23.55B | +38.13% | 0.38% |
| BACK | -11.98% | $1.76M | -32.90% | 0.00% |
| SITC | -11.86% | $847.27M | +59.73% | 2.42% |
| TCTM | -11.63% | $8.10M | -42.99% | 0.00% |
| HUSA | -11.63% | $16.69M | -11.56% | 0.00% |
| MSI | -11.02% | $81.46B | +52.34% | 0.80% |
| TH | -10.92% | $839.02M | -24.49% | 0.00% |
| CHD | -10.63% | $27.18B | +19.50% | 1.03% |
| EG | -10.35% | $15.92B | -8.98% | 2.02% |
| TEO | -10.27% | $1.69B | +87.97% | 0.00% |
| MMC | -10.13% | $108.41B | +10.89% | 1.37% |
ETF's related to STTK
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| KBE | 36.15% | $2.42B | 0.35% |
| XPH | 35.79% | $157.87M | 0.35% |
| RDIV | 35.38% | $842.58M | 0.39% |
| SPIP | 35.24% | $858.31M | 0.12% |
| FALN | 35.21% | $1.84B | 0.25% |
| NUHY | 35.07% | $89.47M | 0.31% |
| FXH | 34.97% | $1.15B | 0.62% |
| PBE | 34.86% | $258.53M | 0.58% |
| GSSC | 34.60% | $529.86M | 0.2% |
| ACES | 34.56% | $124.79M | 0.55% |
| SMDV | 34.50% | $754.57M | 0.4% |
| VIOV | 34.44% | $1.44B | 0.15% |
| FYX | 34.42% | $959.00M | 0.6% |
| IJR | 34.42% | $90.05B | 0.06% |
| RIET | 34.36% | $88.96M | 0.5% |
| GNOM | 34.36% | $70.59M | 0.5% |
| PEY | 34.35% | $1.24B | 0.53% |
| SLYV | 34.32% | $4.16B | 0.15% |
| IWC | 34.30% | $933.99M | 0.6% |
| IJS | 34.30% | $7.37B | 0.18% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| AMDY | -0.19% | $144.24M | 0.99% |
| FLRN | -0.20% | $2.33B | 0.15% |
| DBO | 0.23% | $217.57M | 0.77% |
| KRBN | 0.32% | $242.47M | 0.85% |
| BILZ | -0.37% | $563.02M | 0.14% |
| SGOV | 1.03% | $27.53B | 0.09% |
| SOYB | -1.62% | $27.32M | 0.22% |
| IAK | 1.68% | $760.79M | 0.39% |
| KCCA | -1.97% | $220.51M | 0.87% |
| UNG | 2.13% | $908.80M | 1.06% |
| HIGH | 2.19% | $302.78M | 0.51% |
| DBE | 2.36% | $50.13M | 0.77% |
| DBA | -2.40% | $755.88M | 0.93% |
| TAIL | -2.55% | $67.98M | 0.59% |
| GSG | 2.59% | $914.42M | 0.75% |
| DXJ | 2.99% | $3.71B | 0.48% |
| HDRO | -3.04% | $164.26M | 0.3% |
| JBBB | 3.04% | $1.26B | 0.49% |
| DFSD | 3.26% | $3.63B | 0.16% |
| COMT | 3.29% | $829.06M | 0.48% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -36.54% | $388.04M | 1.43% |
| USDU | -22.19% | $201.97M | 0.5% |
| UUP | -21.04% | $309.25M | 0.77% |
| CTA | -19.26% | $350.27M | 0.78% |
| VIXY | -16.36% | $195.31M | 0.85% |
| WEAT | -12.92% | $120.27M | 0.28% |
| CORN | -10.18% | $61.12M | 0.2% |
| KMLM | -9.45% | $353.87M | 0.9% |
| BOXX | -8.78% | $4.43B | 0.1949% |
| EQLS | -8.67% | $76.08M | 1% |
| JUCY | -7.60% | $324.29M | 0.6% |
| FMF | -6.18% | $244.61M | 0.95% |
| MINT | -4.81% | $11.62B | 0.35% |
| CANE | -4.56% | $17.72M | 0.29% |
| DBMF | -4.16% | $1.02B | 0.85% |
| HDRO | -3.04% | $164.26M | 0.3% |
| TAIL | -2.55% | $67.98M | 0.59% |
| DBA | -2.40% | $755.88M | 0.93% |
| KCCA | -1.97% | $220.51M | 0.87% |
| SOYB | -1.62% | $27.32M | 0.22% |
News
Yahoo
Shattuck Labs ( NASDAQ:STTK ) Third Quarter 2024 Results Key Financial Results Net loss: US$16.7m (loss narrowed by 40...
Yahoo
Shattuck has effectuated its restructuring plan to prioritize the development of the DR3 program and align the Company’s cost and workforce structure with the its current goals and clinical development strategy. The Company has substantially completed the reduction in force associated with the discontinuation of SL-172154. Shattuck believes its cash and cash equivalents and investments will be sufficient to fund its planned operations into 2027, beyond results from its Phase 1 clinical trial of
Yahoo
– Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash balance of approximately $90M as of September 30, 2024; expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of
Finnhub
Engineering Biologics for TNF Receptor Modulation Corporate Overview NASDAQ: STTK November 14, 2024 ...
Finnhub
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights -Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor...
Finnhub
NEW YORK, Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. . Such investors are advised to contact Danielle Peyton at...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.